



Date: 12<sup>th</sup> August, 2025

To,  
Department of Corporate Services  
BSE Limited,  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai - 400 001

Scrip Code: 531569

Sub: Investor Presentation for the First Quarter ended June 30, 2025.

Dear Sir/ Madam,

Please find enclosed herewith Investor Presentation of Sanjivani Paranteral Limited highlighting the performance of the Company during the First Quarter ended June 30, 2025.

Kindly take the above information on your records.

Thanking You,  
Yours Faithfully,

For Sanjivani Paranteral Limited

Ravikumar Bogam  
Company Secretary Cum Compliance Officer



**SANJIVANI**  
PARANTERAL LTD

## **INVESTOR PRESENTATION**

**Q1 FY26**





## Table of Contents

**04**

Market Overview

**07**

About The Company

**13**

Manufacturing  
Facilities

**16**

CDMO Key Clients

**18**

Company's Segment &  
Revenue Mix

**22**

Global Footprint

**24**

Product Portfolio

**28**

Financials

**33**

Stock Information



# Key Financial Highlights

## Q1 FY26



Revenue from Operations  
(up 8.9% Y-o-Y)

**INR 178.9 mn**



EBITDA\*  
(up by 10.8% Y-o-Y)

INR 26.8 mn



PAT  
(up by 1.0% Y-o-Y)

**INR 17.3 mn**



Domestic & Export  
(share in revenue)

26.3% & 73.7%

\*EBITDA: includes other income



## MARKET OVERVIEW





# Global Medicine Market


Use of medicines region wise, Defined Daily Doses (DDD)

Country Name/Year	2018	2019	2020	2021	2022	2023	2024E	2025E	2026E	2027E	2028E	CAGR 2024-2028
Asia-Pacific	451	461	477	507	547	538	559	580	598	618	637	3.4%
Latin America	342	357	438	447	448	461	473	484	489	496	506	1.9%
Western Europe	435	445	444	448	469	463	470	476	481	485	488	1.1%
India	354	359	370	400	390	399	412	428	443	458	474	3.5%
Africa & Middle East	385	395	393	428	425	410	413	424	434	442	451	1.9%
Eastern Europe	332	339	341	358	369	362	370	377	384	388	391	1.6%
China	255	279	271	301	308	308	323	337	349	359	369	3.7%
North America	270	272	270	281	290	290	294	299	303	306	309	1.3%
Japan	141	143	141	145	147	148	149	151	152	152	153	0.6%
Total	2,964	3,049	3,144	3,316	3,394	3,378	3,465	3,556	3,633	3,704	3,778	


Source: IQVIA Institute, Dec 2023.

# Global Medicine Market


**Defined Daily Doses  
(DDD) in billions**



**Global use of  
medicines**



**Global spending  
on medicine**



Source: IQVIA Institute, Dec 2023.



## ABOUT THE COMPANY





# About Us



**Sanjivani Paranteral Ltd (BSE: 531569)** is a pharmaceutical company headquartered in Mumbai and two manufacturing plants at Navi Mumbai and Dehradun, specializing in the manufacturing and distribution of high-quality parenteral and oral solid products. We cater major therapeutic/product areas encompassing CNS, CVS, Antibiotics, Gastroenterological, Anti-Diabetics and Anti-Allergic, supported by a strong R&D set-up.



**WHO-GMP/  
DIGEMID / DDA**

Certified  
Plants



**2**

Manufacturing  
Facilities



**25**

**Countries**

Geographical  
Reach



**~75%**

Exports  
Revenue



**25+ years**

Experience



**720**

**million**

Annual Tablet  
Capacity



**84 million**

Annual Ampoules  
Capacity



**12 million**

Annual Liquid  
injectables Capacity



**120 million**

Annual B Lactam  
Tablet Capacity



**180 million**

Annual B Lactam  
Capsule Capacity



**72 million**


Annual Capsule  
Capacity



**48 million**

Annual Vial  
Capacity

# Significant Milestones of Sanjivani Paranteral Ltd.



# Vision of the Company



## VISION

To be one of India's best research-based pharmaceutical companies, through focus on quality and customer satisfaction.

To bring forth a new paradigm of products & services which lead to unprecedented growth for our stakeholders, customers, strategic partners & team members.

To grow the company on the foundation of Passion, Performance & Partnership.



## MISSION

Creating a world-class organization offering products, services & paradigms that open up new worlds of opportunities.



## VALUES

### 1. Quality

Products that we are proud of

### 2. Customer Satisfaction

Ensuring customer delight


### 3. Growth for all stakeholders

Exceeding stakeholders' expectations is our success mantra

### 4. Professionalism

People you love to work with. A culture of innovative thinking, backed by disciplined execution

# Sanjivani Paranteral's Competitive Advantage



## Experienced Management



**Mr. Ashwani Khemka**  
Chairman & Managing Director



**Mrs. Mrunmai Sarvankar**  
Director



**Mr. Srivardhan Khemka**  
Executive Director



**Mr. Abhay Shah**  
Independent Director



**Ms. Monika A. Singhania**  
Independent Director



**Mr. Pritesh Jain**  
Chief Financial Officer



## MANUFACTURING FACILITIES





## Manufacturing Plant – Alevia HealthCare, Czech Republic



## IV Manufacturing Plant – SPL Infusion Private Limited, Pune





## CDMO KEY CLIENTS





## Injectables



## Oral & Nutraceuticals






## **COMPANY'S SEGMENT & REVENUE MIX**




## Product Category Mix (%)

**Q1 FY26**




**Q1 FY25**






## Geographical Mix (%)

**Q1 FY26**




**Q1 FY25**




## Region-wise Mix (%)

**Q1 FY26**



**Q1 FY25**






## GLOBAL FOOTPRINT



# Global Footprint





## PRODUCT PORTFOLIO



# Product Portfolio





# Product Portfolio

## Urologics



## Anesthetics



## Anesthetics



## Anti Convulsants



## Anti Thyroid Agent



## Anti Fungal



## Anti Emetics



## Anti Depressants



## Anti Histamines



## Anti Diabetic



## Anti-lepemic Agent



## Anti Fibrinolytics



## Anti-bacterials



## Anti-spasmodic



## Anti Hypertensive Agent



## Vitamin Supplement



## Skeletal Muscle Relaxant



## Analgesic & Anti Histaminic



# Product Portfolio

## Non-opioid Analgesics



## Antacids



## Antiseptics



## Nsaids



## Corticosteroids



## Diuretics



## Immunosuppressants



## Narcotic



## Hormone



## Topical Corticosteroids



## Anti Anxiety



## Antibiotic



## Antipsychotic



## Anti Viral



## Narcotics



## Anti- Muscle Relaxant





# FINANCIALS




# Segment-wise Revenue

(Injectables, Oral & Nutraceuticals)




INR Mn.


## INJECTABLES



## ORALS



## NUTRACEUTICALS




# Quarterly Financials

Revenue, EBITDA & Margin, PAT & Margin




INR Mn.


REVENUE\*




EBITDA\*\* & EBITDA Margin



PBT & PBT Margin



PAT & PAT Margin



\*Revenue from Operations (excluding other income) \*\*EBITDA: Includes other income

# Q1 FY26 Profit & Loss Statement




INR Mn.

Particulars	Q1 FY26	Q1 FY25	YoY%	Q4 FY25	QoQ%
Revenue From Operations	178.9	164.4	8.9%	181.8	-1.6%
Other Income	0.4	0.9	-58.1%	4.3	-91.6%
<b>Total Income</b>	<b>179.3</b>	<b>165.2</b>	<b>8.5%</b>	<b>186.1</b>	<b>-3.7%</b>
COGS	111.1	102.6	8.3%	93.9	18.3%
<b>Gross Profit</b>	<b>68.1</b>	<b>62.6</b>	<b>8.8%</b>	<b>92.2</b>	<b>-26.1%</b>
<b>Gross Margin (%)</b>	<b>38.1%</b>	<b>38.1%</b>	<b>-2 bps</b>	<b>50.7%</b>	<b>-</b>
Employee Benefit Exp.	15.2	11.3	34.8%	21.1	-27.9%
Other Expenses	26.1	27.1	-3.8%	40.7	-35.8%
<b>EBITDA incl. other income</b>	<b>26.8</b>	<b>24.2</b>	<b>10.8%</b>	<b>30.4</b>	<b>-11.7%</b>
<b>EBITDA Margin (%)</b>	<b>15.0%</b>	<b>14.7%</b>	<b>26 bps</b>	<b>16.7%</b>	<b>-172 bps</b>
Depreciation	1.6	1.3	23.5%	1.8	-11.0%
Finance Cost	2.2	0.2	-	2.0	8.2%
PBT	23.0	22.7	1.2%	26.5	-13.3%
Tax	5.7	5.6	1.8%	4.7	22.0%
<b>PAT</b>	<b>17.3</b>	<b>17.1</b>	<b>1.0%</b>	<b>21.9</b>	<b>-20.8%</b>
<b>PAT Margin (%)</b>	<b>9.7%</b>	<b>10.4%</b>	<b>-72 bps</b>	<b>11.7%</b>	<b>-209 bps</b>
Basic EPS (in Rs.)	1.46	1.47		1.84	
Diluted EPS (in Rs.)	1.41	1.47		1.61	




# Long Term Growth Drivers




## Stock Information

Shareholding Pattern as on 30<sup>th</sup> June 2025



Stock Information (as on 30<sup>th</sup> June 2025)

Market Cap. (in mn)	2552
Stock Price	214.8
52 Week (High / Low)	397 / 206
BSE – Symbol	531569
Free Float (No. of Shares)	84,51,239
Average Daily Volume (3months) - BSE	6.6k



:



# THANK YOU

**Sanjivani Paranteral Limited**

205, P.N.Kothari Industrial Estate, L.B.S.  
Marg Bhandup (W), Mumbai- 400078, India.

Ph: +91-22-20812600 / 25620515

Email: [corporate@sanjivani.co.in](mailto:corporate@sanjivani.co.in)